-+ 0.00%
-+ 0.00%
-+ 0.00%

Traws Pharma Q3 2026 net loss narrows 10% to $3.55 million

PUBT·11/16/2026 21:36:37
Listen to the news
Traws Pharma Q3 2026 net loss narrows 10% to $3.55 million
  • Traws Pharma’s third-quarter 2026 net loss narrowed 10% year over year to $3.55 million.
  • Cash and cash equivalents fell 39% to $2.34 million at September 30, 2026, from December 31, 2025.
  • An October agreement allows up to $50 million in common stock sales to Roth Principal Investments; no shares have been sold.
  • Positive final Phase 2a ratutrelvir results support planned FDA discussions about a registration strategy for PAXLOVID-ineligible patients.
  • Successful tablet bridging and completed toxicology retesting support a planned fourth-quarter 2026 regulatory resubmission for influenza candidate tivoxavir marboxil.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Traws Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611161635PRIMZONEFULLFEED9878872) on November 16, 2026, and is solely responsible for the information contained therein.